Who We Are
Background and goals of the company:
We are a start-up biotech company (founded in 2023)that developed an active immunization against Alzheimer’s disease (AD), using a unique methionine-sulfoxide (MetO)rich protein, as the antigen. Injecting this antigen to AD-model mice resulted in the auto-production of antibody against MetO, leading to a significant reduction of beta-amyloid peptide and AD-associated markers in brain. Most impressive data was the alleviation of cognitive decline, including both short and long memory deficits in the antigen treated AD-mice. These effects were observed when the AD-phynotypes are highly expressed (10 months of age) , while the treatment was administrated relatively long time before the disease expresses itself (4 months of age). We are currently in the process of advancing this immunization into pre-clinical and clinical trials in humans.
The following link contains the published paper describing our data:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029927/
Additionally, based on the creation of the anti-MetO antibody in rabbit, we are in the process of developing a fast and reliable blood-plasma test that will identify subjects that are at risk of developing AD, or being in advance stages of the disease.
Our team:
Dr. Jackob Moskovitz is the founder and manager of the company. He has more than 20 years of experience in aging and neurodegenerative diseases research. He is currently an Associate Professor in the Department of Pharmacology and Toxicology, School of Pharmacy, at the University of Kansas.
Dr. Moskovitz professional link
Dr. Adam S. Smith is the Scientific director of the company. He has a vast experience in behavioral and molecular function of the mammalian brain both in rodents and human. He is currently an Associate Professor in the Department of Pharmacology and Toxicology, School of Pharmacy, at the University of Kansas.
Dr. Honglian Shi serves as a scientific advisor on oxidative stress and age-associated diseases. He is currently an Associate Professor in the Department of Pharmacology and Toxicology, School of Pharmacy, at the University of Kansas.
Dr. Shoshana Bar-Noy serves as a scientific advisor on vaccination in mammalian research models and humans involved in pre-clinical and clinical trials.Dr. Bar-Noy worked at the NIH, FDA, and Walter Reed Army Institute of Research.
